HealthPhoto: MintFDA Warns of Vision Loss Risk from GLP-1 Diabetes and Weight-Loss Drugs
The US FDA has issued a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION) linked to GLP-1 receptor agonist drugs used for type 2 diabetes and obesity. NAION can cause sudden, painless, and permanent vision loss in one eye. The FDA requires manufacturers to update labels with this risk and advises patients to monitor vision symptoms closely.
Mint·



